Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01623076 · ClinicalTrials.gov registry record

The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders

A clinical trial of Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder, sponsored by University of Texas Southwestern Medical Center.

Active
Registry status
150
Enrollment target
1
Study location

NCT01623076: Active study of Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder, sponsored by University of Texas Southwestern Medical Center.

NCT01623076 is a study of Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder that is active but no longer recruiting, run by University of Texas Southwestern Medical Center. The registered enrollment target is 150 participants, below the 493-participant average among 7 other Neuromyelitis Optica trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01623076, a study of Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder, is active but no longer recruiting, sponsored by University of Texas Southwestern Medical Center.

ACTIVE NOT RECRUITING
Registry status
150 participants
Enrollment target
1
Study location

Study Summary

This study seeks to determine the biologic causes of inflammation in patients with Transverse Myelitis (TM) Neuromyelitis Optica Spectrum Disorder (NMOSD) and related conditions. While patients will be treated according to decisions with their treating physician, this study will collect data and samples from patients prospectively to gain a better understanding of the disease. We are seeking to understand why some patients respond to medications, while others do not. We also seek to understand what happens biologically, preceding relapses. Gathering these data and samples will allow researchers to identify new ways of diagnosing and treating these diseases. Data and samples will be shared with researchers around the world to support collaborative efforts to treat these conditions.

Primary Outcome

Standard clinical assessments include: relapse information, level of disability based on EDSS score, high and low contract visual acuity, ambulation index, optical coherence tomography, and MRI, and neurologic/physical exam

Study Locations (1)

Texas

  • The University of Texas Southwestern Medical Center - Dallas

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2012-06
Est. Completion 2030-06

What the registry record for NCT01623076 still lists

NCT01623076 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 493-participant average among 7 other Neuromyelitis Optica trials with a reported enrollment target (70% lower).

The record links to 4 conditions, with Neuromyelitis Optica appearing as the primary indexed condition, and to 0 interventions.

NCT01623076 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT01623076 about?

NCT01623076 is a clinical study titled "The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders". This study seeks to determine the biologic causes of inflammation in patients with Transverse Myelitis (TM) Neuromyelitis Optica Spectrum Disorder (NMOSD) and related conditions. While patients will be treated according to decisions with their treating physician, this study will collect data and sam...

What is the current status of trial NCT01623076?

This trial is currently active not recruiting. The enrollment target is 150 participants. The study started on 2012-06. Estimated completion is 2030-06.

What conditions does trial NCT01623076 study?

This clinical trial studies the following conditions: Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder, Optic Neuritis, Transverse Myelitis.

Who is sponsoring clinical trial NCT01623076?

This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01623076 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Neuromyelitis Optica

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00412594 · 150 participants · Phase 2

    Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

  • NCT01484730 · 150 participants

    A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion

  • NCT01985919 · 150 participants

    Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

  • NCT02016248 · 150 participants · NA

    SBRT Boost for Unfavorable Prostate Cancer'

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01623076, the US trial registry maintained by the National Library of Medicine. NCT01623076 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.